Ascentage Pharma Group International Future Growth
Future criteria checks 3/6
Ascentage Pharma Group International is forecast to grow earnings and revenue by 53.7% and 26.6% per annum respectively. EPS is expected to grow by 55.2% per annum. Return on equity is forecast to be 49.8% in 3 years.
Key information
53.7%
Earnings growth rate
55.2%
EPS growth rate
| Biotechs earnings growth | 43.4% |
| Revenue growth rate | 26.6% |
| Future return on equity | 49.8% |
| Analyst coverage | Good |
| Last updated | 04 Dec 2024 |
Recent future growth updates
Recent updates
What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You
Dec 23
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up
Sep 04Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt
Aug 26Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up
Jun 18Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year
May 03Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge
Mar 30Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?
Feb 17There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Dec 20Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt
Oct 28Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates
Aug 27There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Aug 23Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt
Jun 19Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?
Dec 04Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?
Aug 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,352 | 774 | 894 | 811 | 6 |
| 12/31/2025 | 497 | -945 | -934 | -809 | 6 |
| 12/31/2024 | 988 | -353 | -365 | -260 | 6 |
| 6/30/2024 | 903 | -360 | -751 | -712 | N/A |
| 3/31/2024 | 563 | -643 | -767 | -719 | N/A |
| 12/31/2023 | 222 | -926 | -783 | -726 | N/A |
| 9/30/2023 | 239 | -902 | -798 | -707 | N/A |
| 6/30/2023 | 257 | -879 | -814 | -687 | N/A |
| 3/31/2023 | 233 | -881 | -852 | -671 | N/A |
| 12/31/2022 | 210 | -883 | -891 | -654 | N/A |
| 9/30/2022 | 160 | -848 | -922 | -620 | N/A |
| 6/30/2022 | 111 | -812 | -954 | -586 | N/A |
| 3/31/2022 | 69 | -797 | -997 | -595 | N/A |
| 12/31/2021 | 28 | -782 | -1,041 | -605 | N/A |
| 9/30/2021 | 25 | -759 | -1,021 | -635 | N/A |
| 6/30/2021 | 23 | -735 | -1,000 | -665 | N/A |
| 3/31/2021 | 18 | -706 | -931 | -637 | N/A |
| 12/31/2020 | 12 | -678 | -861 | -610 | N/A |
| 9/30/2020 | 14 | -922 | -798 | -576 | N/A |
| 6/30/2020 | 15 | -1,167 | -735 | -542 | N/A |
| 3/31/2020 | 15 | -1,324 | -638 | -501 | N/A |
| 12/31/2019 | 15 | -1,481 | -542 | -460 | N/A |
| 9/30/2019 | 11 | -1,171 | -454 | -399 | N/A |
| 6/30/2019 | 7 | -862 | -366 | -338 | N/A |
| 3/31/2019 | 7 | -604 | -310 | -288 | N/A |
| 12/31/2018 | 7 | -345 | -253 | -238 | N/A |
| 12/31/2017 | 6 | -119 | N/A | -108 | N/A |
| 12/31/2016 | 8 | -108 | N/A | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6855 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6855 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6855 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6855's revenue (26.6% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6855's revenue (26.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6855's Return on Equity is forecast to be very high in 3 years time (49.8%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 20:58 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ascentage Pharma Group International is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |